Análisis de la acción Silence Therapeutics PLC (SLN)SLNSilence Therapeutics PLC

Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Silence Therapeutics PLC (SLN) is a good buy right now due to its recent positive developments and potential for growth. The current price is $9.86, and despite a recent 5-day decline of 7.33%, the stock has shown a year-to-date increase of 60.33%. The RSI is at 27.501, indicating that the stock is oversold, which could present a buying opportunity. Additionally, the gross margin has significantly improved to 97.39% in the latest quarter, reflecting strong operational efficiency. However, a key risk is the ongoing net losses, with a reported loss of $12.27 million in Q2 2026, which could impact investor sentiment in the short term.